Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with routine Factor VIII (FVIII) replacement prophylaxis treatment.
Data from largest clinical trial of pre-symptomatic Alzheimer's disease now widely available
- Details
- Category: Research
Fighting antibiotic resistance with peptide cocktails
- Details
- Category: Research
Novel drug application shows improved survival for patients with relapsed and refractory acute myeloid leukemia
- Details
- Category: Research
Study shows ancient viruses fuel modern-day cancers
- Details
- Category: Research
These ancient hitchhikers, known as endogenous retroviruses, were long considered inert or 'junk' DNA, defanged of any ability to do damage. New CU Boulder research published July 17 in the journal Science Advances shows that, when reawakened, they can play a critical role in helping cancer survive and thrive.
Darolutamide meets primary endpoint in Phase III ARANOTE trial
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist danuglipron
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
New AI approach optimizes antibody drugs
- Details
- Category: Research
A comprehensive derivative synthesis method for development of new antimicrobial drugs
- Details
- Category: Research
Efforts to combat the increasing threat of drug-resistant bacteria are being assisted by a new approach for streamlining the search for antimicrobial drug candidates, pioneered by researchers at Hokkaido University, led by Assistant Professor Kazuki Yamamoto and Professor Satoshi Ichikawa of the Faculty of Pharmaceutical Sciences.
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)